TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 645073

Group type: EXPERIMENTAL
Intervention: Dipyrone (20 mg per kg body weight i.v.)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Thermal stimulation
Number of subjects: 16
Study: 31418515

Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Centre-based pulmonary rehabilitation
Number of subjects: 0
Study: 30967135

Group type: EXPERIMENTAL
Intervention: Class II compression stockings (23‐32 mmHg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: No compression stockings (NCS)
Number of subjects: 19
Study: 26628317

Group type: EXPERIMENTAL
Intervention: One-handed chest compression (OHCC) with a 30:2 compression-to-ventilation ratio
Number of subjects: 50

Group type: COMPARATOR
Intervention: Two-handed chest compression
Number of subjects: 50

Group type: COMPARATOR
Intervention: Alternating compression hands every other cycle
Number of subjects: 50
Study: 25895520

Group type: COMPARATOR
Intervention: Suprasensory SNS
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 59

Group type: COMPARATOR
Intervention: Subsensory SNS
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Quality of Life (QoL; SF36)
Number of subjects: 59
Study: 23053764

Group type: EXPERIMENTAL
Intervention: Ultra-short-course chemotherapy (2SHRZ/XHRZ) for an average duration of 4.5 months
Number of subjects: 185

Group type: COMPARATOR
Intervention: Standard chemotherapy for an average duration of 9 months
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Ultra-short-course chemotherapy
Number of subjects: 185
Study: 21739205

Group type: EXPERIMENTAL
Intervention: Conventional tonsillectomy with bipolar diathermy coagulation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Radiofrequency tonsillectomy
Number of subjects: 100
Study: 19489966

Group type: EXPERIMENTAL
Intervention: Metvix cream
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 80
Study: 16728551

Group type: EXPERIMENTAL
Intervention: Testosterone therapy (200 mg i.m. every 2 weeks for 3 months)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 15327915

Group type: EXPERIMENTAL
Intervention: Regular cola (710 ml, 24 oz)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Fat-free raspberry cookies (87 g, 3 oz)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Preload consumed 20 min before test meal
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Preload consumed 2 h before test meal
Number of subjects: 32
Study: 10938022

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (3.0 g eicosapentaenoic acid/docosahexaenoic acid per day)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 55
Study: 9262809

Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7965682

Group type: EXPERIMENTAL
Intervention: Two-step method
Number of subjects: 10

Group type: COMPARATOR
Intervention: One-step method
Number of subjects: 10

Group type: COMPARATOR
Intervention: Midgait method
Number of subjects: 10
Study: 3313686

Group type: EXPERIMENTAL
Intervention: Diltiazem (0.3 mg/kg intravenously)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg sublingually)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 5% glucose (placebo)
Number of subjects: 10
Study: 30038151

Group type: EXPERIMENTAL
Intervention: Oral valproic acid (VPA) 500 mg once a day for 3 months
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group continued on glaucoma therapy (n = 33 eyes)
Number of subjects: 31
Study: 26945271

Group type: EXPERIMENTAL
Intervention: Tolterodine (Detrol LA) extended release daily for 12 weeks
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Intravaginal estradiol cream (Estrace) nightly for 6 weeks then twice per week for 12 weeks
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Combined therapy (intravaginal estradiol + tolterodine) at 24 weeks
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Combined therapy (intravaginal estradiol + tolterodine) at 52 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Tolterodine group
Number of subjects: 58

Group type: COMPARATOR
Intervention: Intravaginal estradiol group
Number of subjects: 58
Study: 25010223

Group type: EXPERIMENTAL
Intervention: Universal decolonization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surveillance and isolation procedures with or without targeted decolonization
Number of subjects: 0
Study: 22918855

Group type: EXPERIMENTAL
Intervention: Test formulation of zolmitriptan 5 mg orodispersible tablet
Number of subjects: 26

Group type: COMPARATOR
Intervention: Reference formulation of zolmitriptan 5 mg orodispersible tablet
Number of subjects: 26
Study: 20360244

Group type: EXPERIMENTAL
Intervention: Viral load measurements using semiquantitative real-time RT-PCR for norovirus diagnosis
Number of subjects: 2000000
Study: 18487744

Group type: EXPERIMENTAL
Intervention: Computer-based scoring tool (tablet PC with standalone scoring application for TISS, SAPS2, and Apache 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, but implied as the traditional scoring method)
Number of subjects: 0
Study: 15787917

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 50

Group type: COMPARATOR
Intervention: Midazolam (0.5 mg x kg(‐1) orally, 30 min before surgery)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 50
Study: 12853806

Group type: EXPERIMENTAL
Intervention: Pelvic muscle exercises (PMEs)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES) for 15 minutes twice daily
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Biofeedback (BFB) for 15 minutes twice daily
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 139
Study: 10391261

Group type: EXPERIMENTAL
Intervention: TMR surgery and medication
Number of subjects: 86

Group type: COMPARATOR
Intervention: Medication group
Number of subjects: 86
Study: 8937258

Group type: EXPERIMENTAL
Intervention: Randomized preventive intervention trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implementation of successful interventions
Number of subjects: 0
Study: 1323943

Group type: EXPERIMENTAL
Intervention: Acyclovir, 800 mg orally five times per day for 7 days
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 6859248

Group type: EXPERIMENTAL
Intervention: Sincere group (S)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Faker group (F)
Number of subjects: 36
Study: 31830963

Group type: EXPERIMENTAL
Intervention: Low-intensity resistance training with heat stress
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (low-intensity resistance training alone)
Number of subjects: 30
Study: 29957401

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) adjuvant therapy to the long down regulation protocol
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (long protocol alone)
Number of subjects: 240
Study: 26756806

Group type: EXPERIMENTAL
Intervention: Whole blood staining before brilliant blue (BB) staining
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional brilliant blue (BB) staining
Number of subjects: 60
Study: 25191933

Group type: EXPERIMENTAL
Intervention: Periacetabular osteotomy (PAO)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 23
Study: 23026181

Group type: EXPERIMENTAL
Intervention: Nasal steroid (mometasone furoate nasal spray)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Antihistamine (fexofenadine)
Number of subjects: 48
Study: 19786416

Group type: EXPERIMENTAL
Intervention: Warm-Supplementing Kidney Yang (WSKY) added to risperidone
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo added to risperidone
Number of subjects: 120
Study: 17463412

Group type: EXPERIMENTAL
Intervention: Roflumilast (500 microg once daily)
Number of subjects: 1513

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1513
Study: 15292338

Group type: EXPERIMENTAL
Intervention: Estrogen (Ovcon 35, 35 microg ethinyl estradiol, and 0.4 mg norethindrone)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Recombinant human IGF-I (30 microg/kg sc twice a day)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Combination of Estrogen and rhIGF-I
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control (rhIGF-I placebo and no E)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: rhIGF-I alone
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Combination of rhIGF-I and E
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Estrogen alone
Number of subjects: 78
Study: 11853331

Group type: EXPERIMENTAL
Intervention: Hyperimmune bovine colostrum (HBC) 100 ml three times a day for 3 days
Number of subjects: 69

Group type: COMPARATOR
Intervention: Bovine colostrum (BC)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: HBC and BC with pivmecillinam 50 mg kg(‐1) d(‐1) for 5 days
Number of subjects: 69
Study: 11477880

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 26

Group type: COMPARATOR
Intervention: Theophylline
Number of subjects: 26
Study: 7868973

Group type: COMPARATOR
Intervention: LDL-apheresis without statin therapy
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: LDL-apheresis with statin therapy (lovastatin or pravastatin)
Number of subjects: 14
Study: 3364227

Group type: EXPERIMENTAL
Intervention: Group Behavioral Marital Therapy (BMT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Interactional Marital Therapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 28899735

Group type: EXPERIMENTAL
Intervention: Bolus ephedrine (7.5-15mg)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Bolus phenylephrine (50-100µg)
Number of subjects: 133
Study: 26686571

Group type: EXPERIMENTAL
Intervention: $5-off Tdap voucher
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Free voucher
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Watching a 1min video PSA about Tdap vaccination
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: No PSA
Number of subjects: 95

Group type: COMPARATOR
Intervention: Retail pharmacy vouchers
Number of subjects: 95
Study: 24815298

Group type: EXPERIMENTAL
Intervention: Probiotic (Symprove) 1 mL/kg/day for 12 weeks
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Probiotic (Symprove)
Number of subjects: 186
Study: 22354361

Group type: EXPERIMENTAL
Intervention: Lichtenstein technique
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Prolene Hernia System (PHS)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: UltraPro Hernia System (UHS)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 309
Study: 20192768

Group type: EXPERIMENTAL
Intervention: Genetic manipulation in Dictyostelium to study chemotaxis
Number of subjects: 0
Study: 18263683

Group type: EXPERIMENTAL
Intervention: Patient-reported depressive symptoms (measured using Geriatric Depression Scale, GDS)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Physician-reported depressive disorders
Number of subjects: 257
Study: 15721727

Group type: EXPERIMENTAL
Intervention: Cisatracurium (CIS) 0.10 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rocuronium (ROC) 0.60 mg/kg
Number of subjects: 40
Study: 12824971

Group type: EXPERIMENTAL
Intervention: 3 days of ampicillin-sulbactam (3 g intravenously every 6 hours)
Number of subjects: 84

Group type: COMPARATOR
Intervention: 7 days of ampicillin-sulbactam (3 g intravenously every 6 hours)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 3 days of ampicillin-sulbactam
Number of subjects: 84

Group type: COMPARATOR
Intervention: 7 days of ampicillin-sulbactam
Number of subjects: 84
Study: 10935147

Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors
Number of subjects: 17255
Study: 8858273

Group type: EXPERIMENTAL
Intervention: Turbuhaler (TBH) 50 micrograms
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Rotahaler (RH) 200 micrograms
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Diskhaler (DH) 200 micrograms
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Turbuhaler (TBH)
Number of subjects: 20
Study: 1495748

Group type: EXPERIMENTAL
Intervention: IL-2 (9 x 10(6) IU/m2, subcutaneously, twice daily for 3 days before surgery)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (18 colon cancer patients)
Number of subjects: 12
Study: 6088166

Group type: EXPERIMENTAL
Intervention: 0.78% sodium monofluorophosphate dentifrice
Number of subjects: 1154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1154
Study: 31348005

Group type: EXPERIMENTAL
Intervention: Transradial access (TRA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Transfemoral access (TFA)
Number of subjects: 60
Study: 29688200

Group type: EXPERIMENTAL
Intervention: Venarus
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard comprehensive conservative treatment
Number of subjects: 80
Study: 25652871

Group type: EXPERIMENTAL
Intervention: In-field gait retraining
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 23445797

Group type: EXPERIMENTAL
Intervention: Landiolol
Number of subjects: 47

Group type: COMPARATOR
Intervention: Diltiazem
Number of subjects: 47
Study: 22149130

Group type: EXPERIMENTAL
Intervention: print‐based feedback
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: phone‐based feedback
Number of subjects: 239

Group type: COMPARATOR
Intervention: contact control
Number of subjects: 239
Study: 20731980

Group type: EXPERIMENTAL
Intervention: Intervention group (usual care plus a 10-minute videotape/DVD and a printed pamphlet)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Usual-care group (advice not to consume alcohol while pregnant and the opportunity to watch a 30-second television commercial)
Number of subjects: 700
Study: 17522901

Group type: EXPERIMENTAL
Intervention: Flap surgery and guided tissue regeneration (GTR)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Flap surgery alone
Number of subjects: 20
Study: 16187469

Group type: EXPERIMENTAL
Intervention: Oral paracetamol
Number of subjects: 300

Group type: COMPARATOR
Intervention: Oral nonsteroidal antiinflammatory drugs (NSAIDs)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Combination therapy (diclofenac-paracetamol)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Diclofenac-paracetamol combination
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: All combinations (NSAIDs, paracetamol, diclofenac-paracetamol)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Patient satisfaction
Number of subjects: 300
Study: 12519847

Group type: COMPARATOR
Intervention: GnRH agonist long protocol (group A; n = 45)
Number of subjects: 142

Group type: COMPARATOR
Intervention: GnRH antagonist protocol commencing recombinant FSH on cycle day 2 (group B; n = 48)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: GnRH antagonist protocol commencing recombinant FSH on cycle day 5 (group C; n = 49)
Number of subjects: 142
Study: 11424663

Group type: EXPERIMENTAL
Intervention: Conditioned medium (CM) by patients T cells
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Conditioned medium (CM) by T cells of healthy donors
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normal bone marrow cells
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Serum Epo level
Number of subjects: 15
Study: 8706778

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 9
Study: 1353803

Group type: EXPERIMENTAL
Intervention: Active nicotine nasal spray (0.5 mg per shot)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Active nicotine nasal spray
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Active nicotine nasal spray and Placebo nasal spray
Number of subjects: 227
Study: 6501724

Group type: EXPERIMENTAL
Intervention: Nifedipine (34 +/- 22 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Hydralazine (10 +/- 5 mg)
Number of subjects: 9
Study: 31182176

Group type: EXPERIMENTAL
Intervention: Psychotropic medication prescribed on discharge (including neuroleptics, antidepressants, anxiolytics)
Number of subjects: 50
Study: 29575951

Group type: EXPERIMENTAL
Intervention: Concurrent training protocol (3 times weekly, 60 minutes per session for 6 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 0
Study: 28879617

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Volume-Matched Moderate-Intensity Continuous Training (CONT)
Number of subjects: 20
Study: 26595966

Group type: EXPERIMENTAL
Intervention: Pulsed low-frequency electrostatic fields (PLIESF)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Combined therapy with PLIESF and therapeutic physical exercises
Number of subjects: 101

Group type: COMPARATOR
Intervention: Therapeutic physical exercises
Number of subjects: 101
Study: 24213914

Group type: EXPERIMENTAL
Intervention: Structured Treatment Interruptions (STIs) consisting of five STIs of 1, 1, 2, 2, and 3 months, respectively, separated by four periods of 3-month therapy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard continuous treatment
Number of subjects: 12
Study: 21144499

Group type: EXPERIMENTAL
Intervention: rTMS targeted at the area of maximal hallucinatory activation calculated from individual fMRI scans during AVH
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: rTMS directed at the left temporoparietal area (TP)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 62
Study: 18065829

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplementation combined with a single bout of resistance exercise (PO + EX)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Oral nutritional supplementation alone (PO)
Number of subjects: 8
Study: 16758243

Group type: EXPERIMENTAL
Intervention: Reboxetine (8 mg/day; n=20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mirtazapine (45 mg/day; n=20)
Number of subjects: 40
Study: 12766690

Group type: EXPERIMENTAL
Intervention: Cognitive-processing therapy
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Prolonged exposure
Number of subjects: 121

Group type: COMPARATOR
Intervention: Delayed-treatment waiting-list condition
Number of subjects: 121
Study: 10848651

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Rabeprazole 40 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 9050084

Group type: EXPERIMENTAL
Intervention: Pimozide (8 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: d-Amphetamine (10 and 20 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pimozide (8 mg) + d-Amphetamine (10 and 20 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1315651

Group type: EXPERIMENTAL
Intervention: Lithium carbonate (800 mg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 6421918

Group type: EXPERIMENTAL
Intervention: 40 mg of sodium cromoglycate (SCG)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo-lactose (P)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Baseline assessment (day 1)
Number of subjects: 16
Study: 31441328

Group type: EXPERIMENTAL
Intervention: Peer-led diabetes prevention workshops (8 sessions, 90 minutes each)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Control group (delayed intervention)
Number of subjects: 402
Study: 30064685

Group type: EXPERIMENTAL
Intervention: Triple positive platelet microparticles (PMPs) expressing phosphatidylserine and integrin complexes alphaIIb (CD41) and beta3 (CD61)
Number of subjects: 193
Study: 27892445

Group type: EXPERIMENTAL
Intervention: Drainage (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No Drainage (Group B)
Number of subjects: 60
Study: 24591191

Group type: EXPERIMENTAL
Intervention: Sublingual administration of D. farinae drops for 48 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo for 48 weeks
Number of subjects: 60
Study: 22112683

Group type: EXPERIMENTAL
Intervention: Prior warfarin only
Number of subjects: 14090

Group type: EXPERIMENTAL
Intervention: Prior ASA and warfarin
Number of subjects: 14090

Group type: COMPARATOR
Intervention: No prior therapy
Number of subjects: 14090

Group type: COMPARATOR
Intervention: Prior ASA only
Number of subjects: 14090
Study: 20391870

Group type: EXPERIMENTAL
Intervention: Chain training (attached chains at 5% of weight)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Traditional training (conventional equipment)
Number of subjects: 19
Study: 17975496

Group type: EXPERIMENTAL
Intervention: Temsirolimus 25 mg
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Temsirolimus 250 mg
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Overall (both doses)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Toxicities reported
Number of subjects: 85
Study: 15777522

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (1000 mg total dose, single blind, one day oral provocation test)
Number of subjects: 20
Study: 12467997

Group type: EXPERIMENTAL
Intervention: Secondary-concomitant fibromyalgia (SCFS)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Fibromyalgia (FS)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Multiregional pain with at least 11 tender points (MPTE)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Widespread pain (WP)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Diffuse multiregional pain (MP)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Healthy subjects (HS)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Cold pressure test
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Von Frey test
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Tourniquet test
Number of subjects: 145
Study: 9481595

Group type: EXPERIMENTAL
Intervention: Reduced fat diet
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Full fat diet
Number of subjects: 220